Literature DB >> 16359290

Polymorphic ventricular tachycardia with a normal QT interval following azithromycin.

Michael H Kim1, Cary Berkowitz, Richard G Trohman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16359290     DOI： 10.1111/j.1540-8159.2005.50146.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN： 0147-8389            Impact factor:   1.976


× No keyword cloud information.
  24 in total

1.  Azithromycin and the risk of cardiovascular death.

Authors:  Wayne A Ray; Katherine T Murray; Kathi Hall; Patrick G Arbogast; C Michael Stein
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

2.  Azithromycin Causes a Novel Proarrhythmic Syndrome.

Authors:  Zhenjiang Yang; Joseph K Prinsen; Kevin R Bersell; Wangzhen Shen; Liudmila Yermalitskaya; Tatiana Sidorova; Paula B Luis; Lynn Hall; Wei Zhang; Liping Du; Ginger Milne; Patrick Tucker; Alfred L George; Courtney M Campbell; Robert A Pickett; Christian M Shaffer; Nagesh Chopra; Tao Yang; Bjorn C Knollmann; Dan M Roden; Katherine T Murray
Journal:  Circ Arrhythm Electrophysiol       Date:  2017-04

3.  Should azithromycin no longer be considered a drug of choice for community-acquired pneumonia because of its potential to cause cardiovascular death?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2013-09

Review 4.  Drug-induced QT prolongation and sudden death.

Authors:  Marc E Del Rosario; Richard Weachter; Greg C Flaker
Journal:  Mo Med       Date:  2010 Jan-Feb

5.  Giant inverted T waves and substantial QT interval prolongation induced by azithromycin in an elderly woman with renal insufficiency.

Authors:  Tongtong Yu; Tiesheng Niu
Journal:  Can Fam Physician       Date:  2014-11       Impact factor: 3.275

6.  Use of azithromycin and risk of ventricular arrhythmia.

Authors:  Gianluca Trifirò; Maria de Ridder; Janet Sultana; Alessandro Oteri; Peter Rijnbeek; Serena Pecchioli; Giampiero Mazzaglia; Irene Bezemer; Edeltraut Garbe; Tania Schink; Elisabetta Poluzzi; Trine Frøslev; Mariam Molokhia; Igor Diemberger; Miriam C J M Sturkenboom
Journal:  CMAJ       Date:  2017-04-18       Impact factor: 8.262

Review 7.  Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Chiara Zuliani; Arno Muller; Herman Goossens; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

Review 8.  Cardiac risks associated with antibiotics: azithromycin and levofloxacin.

Authors:  Zhiqiang Kevin Lu; Jing Yuan; Minghui Li; S Scott Sutton; Gowtham A Rao; Sony Jacob; Charles L Bennett
Journal:  Expert Opin Drug Saf       Date:  2014-12-10       Impact factor: 4.250

9.  Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.

Authors:  Jules C Hancox; Mehrul Hasnain; W Victor R Vieweg; Ericka L Breden Crouse; Adrian Baranchuk
Journal:  Ther Adv Infect Dis       Date:  2013-10

10.  Short-coupled variant of torsade de pointes.

Authors:  K Bogaard; M S van der Steen; H L Tan; R Tukkie
Journal:  Neth Heart J       Date:  2008-08       Impact factor: 2.380
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.